Michael King
Stock Analyst at Rodman & Renshaw
(0.90)
# 3,878
Out of 5,182 analysts
110
Total ratings
37.07%
Success rate
-10.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics | Initiates: Buy | $17 | $1.09 | +1,459.63% | 1 | Mar 17, 2026 | |
| KPTI Karyopharm Therapeutics | Initiates: Buy | $28 | $8.66 | +223.33% | 1 | Mar 10, 2026 | |
| ELTX Elicio Therapeutics | Initiates: Buy | $17 | $11.36 | +49.65% | 1 | Mar 10, 2026 | |
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $13.19 | +4,827.98% | 4 | Apr 1, 2024 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $2.46 | +347.15% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.73 | +1,749.71% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $0.93 | +7,266.38% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | - | - | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $0.83 | +900.00% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $744.44 | +15.79% | 11 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $44.65 | -46.25% | 10 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $166 | $4.09 | +3,958.68% | 8 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $13.10 | +220.61% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $308.51 | -1.46% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $13.04 | +789.57% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.79 | +475.42% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $46.29 | -48.15% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $66.59 | -30.92% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $24.43 | +292.96% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $504 | $8.31 | +5,964.98% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $36.61 | -15.31% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $783.74 | -95.41% | 2 | Nov 13, 2017 |
BioXcel Therapeutics
Mar 17, 2026
Initiates: Buy
Price Target: $17
Current: $1.09
Upside: +1,459.63%
Karyopharm Therapeutics
Mar 10, 2026
Initiates: Buy
Price Target: $28
Current: $8.66
Upside: +223.33%
Elicio Therapeutics
Mar 10, 2026
Initiates: Buy
Price Target: $17
Current: $11.36
Upside: +49.65%
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $13.19
Upside: +4,827.98%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $2.46
Upside: +347.15%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.73
Upside: +1,749.71%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $0.93
Upside: +7,266.38%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: -
Upside: -
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $0.83
Upside: +900.00%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $744.44
Upside: +15.79%
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $44.65
Upside: -46.25%
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $4.09
Upside: +3,958.68%
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $13.10
Upside: +220.61%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $308.51
Upside: -1.46%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $13.04
Upside: +789.57%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $1.79
Upside: +475.42%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $46.29
Upside: -48.15%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $66.59
Upside: -30.92%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $24.43
Upside: +292.96%
Jan 10, 2022
Initiates: Buy
Price Target: $504
Current: $8.31
Upside: +5,964.98%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $36.61
Upside: -15.31%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $783.74
Upside: -95.41%